Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Merck & Co., Inc.
  6. News
  7. Summary
    MRK   US58933Y1055

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about MERCK & CO., INC.
06:46aMerck and Ridgeback's Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine..
BU
01/27Merck & Co.'s Keytruda Wins EU Nod for Adjuvant Treatment of Kidney Cancer
MT
01/27Merck Gets EU Expanded OK for Keytruda in Some Kidney Cancer Patients
DJ
01/27Merck's Keytruda Gets EU Nod for Use as Adjuvant Therapy in Renal Cell Carcinoma
MT
01/27European Commission Approves Merck's KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for ..
BU
01/25Merck & Co. Declares Q2 Dividend of $0.69, Payable April 7 to Shareholders of Record Ma..
MT
01/25Merck Announces Second-Quarter 2022 Dividend
BU
01/25Merck Declares Divined for the First Quarter of 2022, Payable on April 7, 2022
CI
01/24Britain to Start Testing Merck & Co.'s COVID-19 Antiviral Drug
MT
01/24Egypt Clears Merck & Co.'s COVID-19 Pill For Emergency Use
MT
01/24US FDA Declines Approval For Merck &Co.'s New Cough Drug, Seeks Further Information
MT
01/24FDA Declines to Approve Merck's Investigational Cough Treatment Gefapixant
MT
01/24MERCK : FDA Rejects Gefapixant Application, Requests More Data
DJ
01/24Merck Provides U.S. and Japan Regulatory Update for Gefapixant
BU
01/24Merck Provides U.S. and Japan Regulatory Update for Gefapixant
CI
More most relevant news
All news about MERCK & CO., INC.
06:46aMerck and Ridgeback's Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine..
BU
01/27Merck & Co.'s Keytruda Wins EU Nod for Adjuvant Treatment of Kidney Cancer
MT
01/27Merck Gets EU Expanded OK for Keytruda in Some Kidney Cancer Patients
DJ
01/27Merck's Keytruda Gets EU Nod for Use as Adjuvant Therapy in Renal Cell Carcinoma
MT
01/27European Commission Approves Merck's KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for ..
BU
01/26Vaccinex Says Two Patients Showed Complete Response in Study of Combo Drug Treatment fo..
MT
01/25Merck & Co. Declares Q2 Dividend of $0.69, Payable April 7 to Shareholders of Record Ma..
MT
01/25Merck Announces Second-Quarter 2022 Dividend
BU
01/25Merck Declares Divined for the First Quarter of 2022, Payable on April 7, 2022
CI
01/24Britain to Start Testing Merck & Co.'s COVID-19 Antiviral Drug
MT
More news
News in other languages on MERCK & CO., INC.
01/27Keytruda de Merck & Co. reçoit le feu vert de l'UE pour le traitement adjuvant du cance..
01/27MERCK : l'UE approuve le Keytruda pour le cancer du rein
01/27Merck & Co erhält erweitere EU-Zulassung für Keytruda bei Nierenkrebs
01/27Keytruda de Merck reçoit le feu vert de l'UE pour être utilisé comme traitement adjuvan..
01/26Vaccinex déclare que deux patients ont présenté une réponse complète dans une étude sur..
01/25Merck déclare un dividende pour le premier trimestre de 2022, payable le 7 avril 2022
01/24La Grande-Bretagne va commencer à tester le médicament antiviral COVID-19 de Merck & Co..
01/24L'Égypte autorise la pilule COVID-19 de Merck & Co pour une utilisation d'urgence
01/24L'autorité européenne de réglementation des médicaments se prononcera sur l'autorisatio..
01/24La FDA américaine refuse d'approuver le nouveau médicament contre la toux de Merck &Co...
More news
Analyst Recommendations on MERCK & CO., INC.
2021Daiwa Securities Starts Merck & Co. at Neutral With $70 Price Target
MT
2021ANALYST RECOMMENDATIONS : AT&T, BioNTech, Columbia Sports, Jefferies, Under Armour...
2021UBS Downgrades Merck & Co. to Neutral from Buy, Adjusts Price Target to $76 from $98
MT
2021Wells Fargo Starts Merck at Overweight With $90 Price Target
MT
2021Guggenheim Downgrades Merck to Neutral From Buy
MT
More recommendations
Press releases
06:46aMerck and Ridgeback's Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine..
BU
01/27European Commission Approves Merck's KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for ..
BU
01/25Merck Announces Second-Quarter 2022 Dividend
BU
01/24Merck Provides U.S. and Japan Regulatory Update for Gefapixant
BU
01/21Strides and its African subsidiary Universal Corporation partner with Medicines Patent
AQ
More press releases
Analysis
Merck sees up to $7 billion in sales of COVID-19 drug through end of 2022
Stock Pick
 MERCK AND COMPANY
Leader in oncology, modest valuation
Official Publications
2021Dividends 
2021SEC Filing 10Q-3 
2021Press Release 
20213rd quarter results 
2021SEC Filing 8K 
2021Nomination 
Upcoming event on MERCK & CO., INC.
02/03/22FY 2021 Earnings Release
Upcoming sector events
02/02/22ABBVIE INC. : FY 2021 Earnings Release
02/02/22NOVO NORDISK A/S : FY 2021 Earnings Release
02/03/22ROCHE HOLDING AG : FY 2021 Earnings Release
02/08/22PFIZER INC. : FY 2021 Earnings Release
Sector
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Other Pharmaceuticals